-
Hangzhou Chance Pharmaceuticals Secures New Funding for Inhalation Powder Aerosol Development
•
Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s “4+1” Biomedical and High-end Medical Device Industry Fund and Qihang Investment Management Co., Ltd., with Lighthouse Capital serving as the exclusive financial advisor. The funds will propel the Phase III clinical trial of CXG87, a…
-
Hangzhou Chance Pharmaceuticals Partners with Yiling Pharmaceutical for Inhalation Powder Development
•
China’s Hangzhou Chance Pharmaceuticals Co., Ltd., a specialist in lung drug delivery, has entered into a partnership with fellow Chinese firm Yiling Pharmaceutical Co., Ltd (SHE: 002603). The collaboration aims to leverage Hangzhou Chance’s experience and technology in the development of inhalation powder mist agents, thereby facilitating Yiling Pharma in…
-
Acorda Therapeutics Strikes Deal with Hangzhou Chance for Inbrija Distribution in China
•
US-based Acorda Therapeutics Inc., (Nasdaq: ACOR) has announced a distribution and supply agreement with Hangzhou Chance Pharmaceuticals Co., Ltd, a Chinese pharmaceutical company. This deal will facilitate the supply of Inbrija (levodopa inhalation powder) to the mainland China market, where it will be used as an intermittent treatment for episodic…
